Literature DB >> 3001123

Modulation of lactogenic receptors by progestins in cultured human breast cancer cells.

L J Murphy, L C Murphy, B Stead, R L Sutherland, L Lazarus.   

Abstract

Progesterone receptors (PgR) are present in many breast cancers, but few specific actions of progestins in breast cancer cells have been reported. We now report that progestins specifically modulate lactogenic receptor expression in cultured T-47D and MCF-7 human mammary carcinoma cells. When T-47D cells were preincubated for 24 h with 1 nM medroxyprogesterone acetate (17 alpha-acetoxy-6 alpha-methyl-4-pregnene-3,20-dione), specific binding of [125I]human GH ([125I]hGH) and [125I]human PRL was increased to 205 +/- 22% (+/- SE) (P less than 0.01) and 175 +/- 32% (P less than 0.05), respectively, of that in control cultures. There was no significant effect on cell number and no significant enhancement of specific binding of [125I]porcine insulin, [125I]salmon calcitonin, [125I]human transferrin, or [3H] Concanavalin A. Lactogenic receptor number was increased from 6,490 +/- 500 (n = 12) to 13,180 +/- 3,270 (n = 7; P less than 0.01) sites/cell, with no significant change in affinity for hGH. Progesterone, which is readily metabolized by these cells, was less potent than the synthetic progestins (medroxyprogesterone acetate, R 5020 (17 alpha, 21-dimethyl-19-norpregn-4,9-diene-3,20-dione), and ORG 2058 (16 alpha-ethyl-21-hydroxy-19-norpregn-4-en-3,20-dione), but physiological concentrations of progesterone (1 nM) significantly enhanced specific binding of [125I]hGH to 153 +/- 23% of the control value (n = 6; P less than 0.05). Physiological concentrations of androgens, estrogens, and glucocorticoids had no significant effect. MCF-7 cells were considerably less sensitive to these effects of progestins than T-47D cells, probably due to the lower PgR concentration in MCF-7 cells. These observations, which indicate that lactogenic receptor expression is controlled, at least in part, by progestins in these mammary carcinoma cell lines, may have important implications in the management of human breast cancer, where high levels of this receptor may reflect a functional PgR and a highly hormone-dependent phenotype.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3001123     DOI: 10.1210/jcem-62-2-280

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Prepubertal gynecomastia a rare complication of growth hormone therapy.

Authors:  Shrikrishna V Acharya; Raju A Gopal; Tushar R Bandgar; Padma S Menon; Nalini S Shah
Journal:  Indian J Pediatr       Date:  2010-02-08       Impact factor: 1.967

2.  Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP.

Authors:  Anita S Goldhar; Renqin Duan; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Mol Cell Endocrinol       Date:  2011-01-14       Impact factor: 4.102

3.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

4.  Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens.

Authors:  A Coutts; L J Murphy; L C Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  The effect of age and menstrual cycle upon proliferative activity of the normal human breast.

Authors:  C S Potten; R J Watson; G T Williams; S Tickle; S A Roberts; M Harris; A Howell
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.